BI part­ners with Ts­inghua for im­muno ther­a­pies

BioSpectrum (Asia) - - Academic News -

Boehringer In­gel­heim (BI) and Ts­inghua Univer­sity in Bei­jing have an­nounced a col­lab­o­ra­tion aim­ing to re­search and de­velop im­muno­log­i­cal ther­a­pies for in­fec­tious dis­eases. Sci­en­tists will work in the BI-Ts­inghua Univer­sity Joint Re­search Cen­tre for Im­muno-In­fec­tion to har­ness the mech­a­nisms of im­mune mod­u­la­tion to com­bat in­fec­tious dis­eases. The col­lab­o­ra­tion brings to­gether the lead­ing ex­per­tise of Ts­inghua Univer­sity in in­fec­tious dis­ease re­search and im­munol­ogy with Boehringer In­gel­heim’s ex­pe­ri­ence in the de­vel­op­ment of novel ther­a­pies for pa­tients suf­fer­ing from dis­eases with high un­met med­i­cal need and its com­pre­hen­sive re­search and de­vel­op­ment pro­grams in can­cer im­munol­ogy and im­mune mod­u­la­tion. This col­lab­o­ra­tion is an ini­tia­tive of Boehringer In­gel­heim’s Re­search Be­yond Bor­ders

(RBB) and Can­cer Im­munol­ogy and Im­mune Mod­u­la­tion Re­search De­part­ments. Im­muno-in­fec­tion is a new fo­cus area for BI’s RBB depart­ment, which also fo­cuses on gene ther­apy, re­gen­er­a­tive medicine and the role of the mi­cro­biome in hu­man health and dis­ease. With the new col­lab­o­ra­tion, BI fur­ther ex­pands its ac­tiv­i­ties in the grow­ing bio­med­i­cal in­no­va­tion hot spot of China. By com­bin­ing a fo­cus on cut­ting-edge science with a long-term view, the com­pany aspires to de­velop the next gen­er­a­tion of med­i­cal break­throughs to im­prove the lives of pa­tients suf­fer­ing from dis­eases with high un­met med­i­cal needs.

Newspapers in English

Newspapers from India

© PressReader. All rights reserved.